[A26-12] Sotatercept (pulmonary arterial hypertension, WHO functional class IV) – Benefit assessment according to §35a Social Code Book V
Last updated 06.08.2026
Project no.:
A26-12
Commission:
Commission awarded on 16.02.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Adults with WHO functional class IV PAH
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-12
| Project no. | Title | Status |
|---|---|---|
| A24-96 | Sotatercept (pulmonary arterial hypertension) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A26-75 | Sotatercept (pulmonary arterial hypertension, WHO functional class IV) – Addendum to Commission A26-12 | Commission completed |
Federal Joint Committee (G-BA)
06-08-2026 A G-BA decision was published.
G-BA documents on this decision